Large-scale cross-population genome-wide association study (GWAS) meta-analyses have substantially enhanced the statistical power to uncover novel disease/phenotype-associated genetic loci and facilitate disease risk prediction. A trans-ancestry GWAS meta-analysis of 457,690 individuals identified 183 serum urate-associated loci, including 147 novel loci, and validated the regulatory effect of HNF4A on urate metabolism. These urate-associated loci were further combined into a weighted genetic risk score (GRS) that improved gout risk prediction among 334,880 UK Biobank participants. The GRS alone showed moderate discrimination, whereas its addition to age and sex increased the cross-validated area under the receiver operating characteristic curve (AUC) from 0.78 to 0.83, suggesting that genetic information may complement conventional risk factors in identifying individuals with a high inherited susceptibility to gout^[8].

Complementing this large-scale locus discovery, a trans-ancestry study integrating European and East Asian serum urate GWAS data used UK Biobank data for linkage disequilibrium estimation and replication of gout associations. Subsequent expression quantitative trait locus (eQTL) colocalization and functional fine-mapping identified candidate causal genes at 24 serum urate-associated loci, providing further insight into the molecular mechanisms underlying urate control^[32]. Additionally, by using large-cohort genotypic and phenotypic data from the UK Biobank, twelve novel single nucleotide polymorphisms (SNPs), located in ABCG2, SLC2A9, SLC22A11, GCKR, MEPE, PPM1K-DT, LOC105377323 and ADH1B, associated with the progression from hyperuricemia to gout were identified in 2021, providing novel insights into the underlying pathogenic mechanisms of gout^[11]. More recent studies have further refined the genetic architecture of clinical gout. A large multi-ancestry GWAS meta-analysis of 2.6 million individuals, including UK Biobank participants, identified 377 loci and 410 genetically independent signals and prioritized pathways involving epigenetic remodeling, cellular osmolarity, and NLRP3 inflammasome regulation, thereby extending genetic research beyond urate transport and metabolism to gout-specific inflammatory mechanisms^[12]. Using a refined gout phenotype derived from the 2019 UK Biobank pain questionnaire, another GWAS identified 13 gout-associated loci, 10 of which were replicated in FinnGen, and also revealed sex-specific patterns of genetic association^[13].

From a clinical perspective, genetic risk scores may complement established clinical factors in identifying individuals with a high inherited susceptibility to gout, but their routine use for gout risk stratification remains premature. Gout-specific intervention thresholds and prospective evidence that polygenic risk score (PRS)-guided risk stratification improves clinical outcomes have not yet been established, and appropriate validation, calibration, and interpretation are required before clinical implementation^[33]. Ethical implementation also requires careful communication of probabilistic genetic risk, informed decision-making, protection against misuse of genetic information, and attention to potential inequities in PRS performance across populations^[33,34].

Adiposity is among the most consistently supported modifiable determinants of hyperuricemia and gout. UK Biobank-based and genetically informed analyses have linked higher body mass index and obesity to elevated serum urate and a greater risk of gout^[15,35]. These findings are broadly consistent with external prospective cohorts in both men and women, which identified obesity as an important predictor of incident gout and of progression from asymptomatic hyperuricemia to clinical disease^[36,37]. The agreement between observational and genetically informed evidence makes adiposity one of the more robust risk factors identified in this field.

The metabolic consequences of obesity may be as important as body size. Bidirectional Mendelian randomization analyses supported a directional effect of hyperinsulinemia on serum urate and gout, whereas evidence for an effect in the reverse direction was weaker^[14]. An external study combining Mendelian randomization with network pharmacology suggested insulin resistance as a potential mechanistic link between obesity and hyperuricemia^[38]. Hyperinsulinemia may reduce renal urate excretion and frequently coexists with dyslipidemia, hypertension, and visceral fat accumulation. These findings support a metabolic pathway linking adiposity, insulin resistance, hyperuricemia, and gout, although the relative contributions of renal urate handling, dietary intake, inflammation, and other metabolic abnormalities remain difficult to separate.

Genetic susceptibility also remains relevant across different levels of adiposity. UK Biobank analyses showed that urate-associated variants continued to influence gout risk across body mass index categories^[10]. This indicates that obesity and genetic predisposition should not be viewed as mutually exclusive explanations. Instead, they may contribute jointly to disease development. However, existing studies do not establish a specific body mass index or visceral adiposity threshold that can be used to guide gout prevention.

Age-related biological changes have emerged as a related but less established area of research. A UK Biobank cohort study associated accelerated biological aging with progression from hyperuricemia to gout^[39]. Separately, a cross-sectional and Mendelian randomization study reported an association between frailty and gout^[40]. Other analyses have examined relationships among serum urate, telomere length, and inflammatory markers^[41]. Although these findings point in a broadly consistent direction, biological age, frailty, and telomere length measure different aspects of aging and cannot be treated as interchangeable exposures. Evidence that biological aging independently drives progression to gout remains preliminary and requires validation in cohorts with repeated measurements and well-defined hyperuricemia-to-gout transitions.

Alcohol is one of the clearest examples of concordant UK Biobank and external evidence. In the UK Biobank, higher total alcohol consumption and several beverage-specific exposures were associated with a higher risk of incident gout, with variation by sex, dose, and beverage type^[18]. In this analysis, among current drinkers, consuming alcohol five or more times per week, compared with less than once per week, was associated with a higher risk of gout in both men (HR: 2.05, 95%CI: 1.84-2.30) and women (HR: 1.34, 95%CI: 1.12-1.61). UK Biobank genetic analyses also suggested gene-environment interactions involving alcohol-related loci and gout susceptibility^[42]. These findings are consistent with external prospective cohort evidence showing that alcohol intake, particularly beer and spirits, increased incident gout risk in men^[43]. External case-crossover evidence further showed that alcohol intake shortly before an attack was associated with recurrent gout flares^[44]. Therefore, alcohol can be discussed as a relatively well-supported modifiable risk factor, although the magnitude of risk depends on dose, beverage type, sex, and baseline metabolic status.

Coffee shows a more complex pattern. UK Biobank observational evidence supports an inverse association between coffee consumption and gout risk. A UK Biobank prospective analysis found nonlinear inverse associations between tea or coffee intake and incident gout^[45]. External prospective cohorts in men and women reported similar inverse associations between coffee consumption and incident gout^[46,47]. However, genetically informed studies have produced less consistent conclusions. The UK Biobank mediation analysis suggested that shared genetic variants largely influenced gout directly rather than through coffee intake^[48]. A UK Biobank Mendelian randomization-phenome-wide association study (MR-PheWAS) of habitual coffee consumption also provided limited evidence that genetically predicted coffee intake produced broad disease-protective effects^[49]. In contrast, external Mendelian randomization and mediation MR studies reported a potential protective association of coffee intake with gout, possibly involving serum urate, urea, or sex hormone-binding globulin^[50,51]. These differences may reflect the choice of genetic instruments, pleiotropy, exposure definition, coffee subtype, caffeine content, and differences between lifelong genetic predisposition and actual drinking behavior. Thus, coffee consumption is consistently associated with lower gout risk in observational studies, but current causal evidence remains insufficient to recommend increased coffee intake specifically for gout prevention.

Evidence for tea is more limited and should be interpreted separately from coffee. The UK Biobank prospective analysis suggested that tea intake was associated with gout risk in a nonlinear manner, with the lowest risk observed at relatively high intake levels. In that study, participants consuming more than six cups of tea per day had a lower risk of incident gout than non-tea drinkers (HR: 0.77, 95%CI: 0.66-0.91), and spline analyses suggested that the inverse association became apparent at approximately six cups per day^[45]. However, Mendelian randomization evidence was less consistent. A separate MR study reported no clear causal association of tea intake with overall gout, idiopathic gout, or serum urate, although a weak inverse association was observed for gout due to impaired renal function^[52]. Therefore, current tea-related evidence suggests a possible inverse association but remains insufficient to support a firm conclusion regarding gout prevention.

Studies of broader dietary patterns highlight the need to distinguish specific dietary components from the overall contribution of diet to serum urate variability. Several UK Biobank studies have examined dietary quality or specific food groups. Higher consumption of ultra-processed foods was associated with a higher risk of gout in the UK Biobank and appeared to have an additive effect with genetic susceptibility^[53]. Compared with participants in the lowest quartile of ultra-processed food consumption, those in the highest quartile had a higher risk of gout (HR: 1.16, 95%CI: 1.01-1.33). Participants with both high ultra-processed food consumption and high genetic predisposition had an even higher risk than those with low consumption and low genetic predisposition (HR: 1.90, 95%CI: 1.39-2.60). UK Biobank analyses of carbohydrate intake further showed that carbohydrate quality and source were more informative than total carbohydrate intake alone, with free sugars and less favorable carbohydrate profiles associated with higher gout risk^[54]. A UK Biobank-derived low-urate dietary index was also associated with lower incident gout risk and was further evaluated in external cohorts, where the overall direction of association was broadly consistent^[55]. These findings support the relevance of dietary quality, but most individual dietary exposures require further replication.

At the same time, non-UKB and mixed-cohort evidence suggests that diet explains only a limited proportion of serum urate variation compared with genetic and metabolic determinants. A diet-wide meta-analysis based on five United States cohorts, not the UK Biobank, found that dietary factors explained only a small fraction of variation in serum urate levels^[56]. A subsequent multi-cohort analysis including UK Biobank and external cohorts similarly concluded that diet had a relatively weak causal contribution to hyperuricemia compared with genetic, metabolic, and clinical factors^[57]. These findings are not necessarily inconsistent with UK Biobank studies identifying specific dietary risk factors. A broad dietary contribution to serum urate variation can be modest while particular foods, nutrients, or dietary patterns still show meaningful associations with gout risk.

Fatty acid research represents another emerging dietary direction. UK Biobank-based cohort and Mendelian randomization analyses associated higher circulating or dietary linoleic acid and some n-6 polyunsaturated fatty acid measures with lower gout risk^[58,59]. The direction of evidence is internally consistent across these UK Biobank-related analyses, but these findings should not be generalized to all polyunsaturated fatty acids, because different fatty acid subtypes may have distinct associations. External replication and intervention studies are still needed before these results can be translated into gout-specific dietary recommendations.

Observational evidence from the UK Biobank generally supports an inverse association between physical activity and incident gout. Greater purposeful steps combining walking volume and intensity, a more regular weekly distribution of accelerometer-measured moderate-to-vigorous physical activity, and higher walking activity across polygenic risk strata were each associated with a lower risk of incident gout^[60-62]. However, genetically informed evidence is less consistent and appears to vary according to the outcome assessed. One Mendelian randomization study found that genetically predicted physical activity was associated with lower serum urate but not with gout^[63], whereas another suggested that moderate-intensity physical activity may reduce gout risk without a clear effect on serum urate^[64]. Differences in physical activity definitions, genetic instruments, outcome datasets, and statistical power may partly explain these divergent findings. Taken together, current evidence supports physical activity as part of a favorable gout risk profile, but does not yet establish an independent causal effect on gout.

Sleep has received less attention. A UK Biobank prospective study found that healthier sleep patterns were associated with a lower risk of new-onset gout^[17]. Compared with participants with poor sleep patterns, those with healthy sleep patterns had a 21% lower risk of new-onset gout (HR: 0.79, 95%CI: 0.70-0.91). A separate UK Biobank analysis focusing on sleep duration and hyperuricemia reported that short sleep duration was associated with hyperuricemia, particularly among women^[65]. These findings are directionally compatible, but sleep duration, sleep quality, chronotype, insomnia, and sleep apnea are distinct exposures. Their relationships with gout may also be confounded or mediated by obesity, depression, cardiometabolic disease, shift work, and medication use. Current evidence supports considering sleep health as a potential component of overall gout risk, but not as a single well-defined causal factor.

Smoking remains one of the least consistent lifestyle-related factors. In UK Biobank gout research, smoking has mainly been included as part of composite healthy lifestyle scores rather than evaluated as an independent exposure. A UK Biobank analysis showed that a healthier lifestyle score was associated with lower gout risk and attenuated part of the excess risk associated with genetic susceptibility^[16]. However, this does not prove that non-smoking alone independently lowers gout risk. External studies have reported conflicting findings: one prospective study in men observed a lower incidence of gout among current smokers^[66], whereas another study in older adults found that some smoking-related measures were associated with a higher subsequent risk of gout^[67]. These counterintuitive and inconsistent results may reflect differences in smoking definitions, former-smoker classification, competing risks, body weight, and residual confounding. Smoking should still be discouraged because of its well-established systemic harms, but the current literature does not support presenting smoking avoidance as an independently proven gout-specific preventive factor.

Medication-related evidence in UK Biobank studies has focused mainly on diuretics, metformin, sodium-glucose cotransporter inhibition, and glucosamine supplementation. These medications and related exposures may influence serum urate or gout risk through renal urate transport, metabolic pathways, or interactions with genetic susceptibility. Among them, the most consistent evidence concerns diuretics. UK Biobank research showed that serum urate-associated genetic variants continued to contribute strongly to gout risk among individuals taking diuretics^[68]. Another UK Biobank genome-wide analysis of thiazide-induced adverse metabolic effects found genetic determinants of thiazide-associated hyperuricemia^[69]. These UK Biobank findings are supported by external cohort evidence from the Atherosclerosis Risk in Communities (ARIC) study, which reported a urate gene-by-diuretic interaction and higher gout risk among hypertensive participants using thiazide or loop diuretics^[70]. Earlier external prospective cohorts also identified diuretic use as a predictor of incident gout in men and women^[36,37]. Overall, diuretic exposure is one of the medication-related factors with relatively consistent evidence. Clinically, this supports careful risk assessment rather than discontinuation of necessary antihypertensive therapy.

The evidence for metformin is less consistent and depends on the outcome. A UK Biobank analysis found that metformin use was associated with lower serum urate, but evidence for a corresponding reduction in incident gout was less convincing^[19]. In contrast, an external target-trial emulation study in adults with prediabetes reported that metformin initiation was associated with a lower risk of gout^[71]. Differences in baseline metabolic status, comparator groups, medication adherence, exposure duration, and endpoint definition may explain this discrepancy. Therefore, metformin should be described as a drug with potential urate-lowering relevance, but not as an established gout-preventive therapy.

Sodium-glucose cotransporter inhibition provides a related but distinct example. A genetic proxy analysis using a UK Biobank-derived SGLT1 instrument found that genetically proxied SGLT1 inhibition was associated with lower serum urate and gout risk^[72]. External comparative-effectiveness studies of clinical SGLT2 inhibitor use reported lower risks of incident or recurrent gout compared with several other glucose-lowering therapies^[73,74]. These findings are directionally coherent, but they do not evaluate the same exposure: SGLT1 genetic proxies and SGLT2 inhibitor treatment differ biologically and clinically. Randomized trials or well-designed comparative studies with gout-specific endpoints would be required before drawing therapeutic conclusions.

Habitual glucosamine supplementation was associated with a lower incidence of gout among women in a UK Biobank study, whereas no clear association was observed among men^[20]. No directly comparable independent replication was identified in the targeted external search. This finding should therefore be presented as a sex-specific, hypothesis-generating drug-repurposing signal rather than established evidence of benefit. Healthy-user behavior and differences in healthcare engagement may partly explain the association.

Air pollution is the environmental exposure with the clearest convergence between UK Biobank and external evidence. Two UK Biobank prospective studies associated long-term exposure to particulate matter, nitrogen dioxide, nitrogen oxides, or combined air pollutants with higher incident gout risk^[21,22]. For example, each interquartile-range increase in PM_2.5 and NO₂ exposure was associated with a 5% (HR: 1.05, 95%CI: 1.02-1.09) and 8% (HR: 1.08, 95%CI: 1.05-1.12) higher risk of incident gout, respectively^[21]. Some analyses suggested that the associations varied by age, genetic risk, or circulating biomarkers^[22]. External studies in non-UKB populations similarly linked ambient air pollution to higher serum urate concentrations or increased hyperuricemia risk^[75-77]. The direction of evidence is therefore broadly consistent across populations.

However, the evidence remains predominantly observational. In the UK Biobank, air pollution exposure is generally estimated from residential location and may not fully capture migration, indoor pollution, occupational exposure, commuting patterns, or individual time-activity behavior. Air pollution is also correlated with socioeconomic status, urbanization, noise, physical activity opportunities, and healthcare access. Thus, air pollution can be described as a consistent environmental correlate of hyperuricemia and gout, but not yet as an independently established causal factor.

Domestic water hardness is a relatively new and underexplored exposure. A UK Biobank study linked higher domestic water hardness and higher calcium- or magnesium-related water metrics to incident or recurrent gout^[78]. No directly comparable external gout studies were identified, and existing non-UKB research has focused on urinary electrolytes or kidney stone outcomes rather than gout^[79]. Thus, this finding remains exploratory and requires independent validation.

Sex hormone evidence illustrates why exposure definitions matter. A UK Biobank cohort analysis found that higher total testosterone was associated with lower gout risk in men, whereas free testosterone and bioavailable testosterone showed associations in the opposite direction^[23]. Genetically informed analyses also supported inverse associations of total testosterone and sex hormone-binding globulin (SHBG) with gout risk^[80], although free and bioavailable testosterone were not evaluated in the same manner. These measure-specific findings suggest that total testosterone, free testosterone, bioavailable testosterone, and SHBG capture different hormonal and metabolic states and should not be interpreted as interchangeable exposures.

UK Biobank research has also increasingly investigated circulating biomarkers associated with gout development and recurrence. A UK Biobank prospective metabolomic study found that prediagnostic GlycA concentrations were associated with incident gout and recurrent flares after accounting for serum urate, with Mendelian randomization analyses in the same study providing additional support for a potential inflammatory pathway^[24]. The internal consistency between prospective and genetic analyses strengthens the finding, but no directly comparable external replication was identified. GlycA should therefore be described as a promising inflammatory marker beyond serum urate, not as a clinically validated prediction tool.

Metabolomic evidence is also emerging. A UK Biobank metabolome-wide study identified several amino acids and related metabolites associated with incident or hospitalized gout, accounting for serum urate^[81]. However, the direction of association differed across metabolites, and the findings may be sensitive to multiple testing, renal function, diet, and correlated metabolic traits. Because no directly comparable external replication was identified, these results should be presented as exploratory and hypothesis-generating.

Clonal hematopoiesis provides a stronger example of convergence across data sources. A study using UK Biobank and Mass General Brigham Biobank data found that TET2-mutant clonal hematopoiesis was associated with a higher risk of gout, and experimental work supported a potential NLRP3-interleukin-1β inflammatory mechanism^[25]. This combination of UKB evidence, an external biobank, and mechanistic validation provides stronger support than a single-cohort association. Nevertheless, the finding should not be generalized to all forms of clonal hematopoiesis, and its implications for clinical screening or prevention remain uncertain.

Impaired pulmonary function is another emerging factor mainly supported by UK Biobank evidence. An integrated UK Biobank study combining longitudinal observation, Mendelian randomization, and mediation analysis associated impaired pulmonary function with higher gout risk and suggested possible roles for serum urate and inflammatory biomarkers^[30]. The use of multiple analytical strategies improves internal consistency, but no directly comparable external replication was identified. This topic should therefore be described as a novel research direction rather than an established gout risk factor.

Overall, the available evidence does not support treating all gout-related factors as equally established. Adiposity, insulin resistance, alcohol consumption, diuretic use, and air pollution show relatively consistent associations across UK Biobank and external studies, although causal certainty varies by exposure. Coffee consumption, physical activity, smoking, metformin use, and sex hormone measures require more cautious interpretation because findings differ according to exposure definition, analytical method, or clinical endpoint. Other factors, including biological aging, domestic water hardness, GlycA, amino acid metabolites, glucosamine, and pulmonary function, are best regarded as emerging areas that require independent replication. These patterns are summarized in Table 1, which distinguishes relatively consistent, partially concordant, conflicting, and emerging evidence.

Cardiometabolic disease represents the most clinically relevant comorbidity cluster in gout. A UK Biobank case-control study showed that hypertension, ischemic heart disease, congestive heart failure, hyperlipidemia, and diabetes were more common among individuals with gout than among controls. Some associations persisted after accounting for serum urate, suggesting that the systemic burden of gout may not be explained by urate concentration alone^[26]. Earlier external cohort evidence also indicated that hypertension may predict incident gout independently of serum urate, supporting a bidirectional clinical relationship between blood pressure, urate metabolism, and gout risk^[82].

Large-scale UK Biobank and genetic studies further indicate that hyperuricemia and gout are associated with higher cardiovascular risk, but causal interpretation remains complex. A cohort and Mendelian randomization analysis found that individuals with hyperuricemia or gout had increased risks of several cardiovascular diseases, although genetic evidence did not uniformly support a direct causal effect of gout itself across all cardiovascular outcomes^[27]. Similarly, Mendelian randomization and phenome-wide analyses suggested that serum urate may act partly as a marker of shared cardiometabolic pathways rather than a universal causal driver of cardiovascular disease^[83-85].

From a clinical perspective, these findings support systematic cardiovascular risk assessment in patients with gout, including evaluation of blood pressure, lipid levels, diabetes, obesity, renal function, and medication use. However, they do not justify assuming that urate-lowering therapy alone will reduce cardiovascular risk. More recent UK Biobank studies suggest that favorable lifestyle and metabolic profiles are associated with lower cardiovascular risk among individuals with gout or high genetic susceptibility to gout^[86,87]. Thus, gout should be regarded as a practical cue for broader cardiometabolic prevention rather than merely as an indication for serum urate control.

The relationship between serum urate, gout, and kidney disease is clinically important but causally uncertain. Observational studies consistently link higher serum urate with lower estimated glomerular filtration rate and higher chronic kidney disease risk. However, Mendelian randomization analyses using UK Biobank-linked and external genetic data did not support a causal effect of serum urate on estimated glomerular filtration rate or chronic kidney disease risk^[88]. A UK Biobank Mendelian randomization analysis similarly found no convincing causal effect of serum urate on urolithiasis, despite observational associations between hyperuricemia and stone disease^[28]. These findings suggest that renal comorbidities in gout may often reflect shared risk factors, including hypertension, diabetes, obesity, diuretic use, and reduced renal urate excretion.

For clinicians, the key message is that kidney function should be assessed routinely in patients with gout because it affects urate handling, drug selection, and cardiovascular risk. However, current genetic evidence does not support lowering serum urate solely to prevent chronic kidney disease in individuals without gout-specific indications. The clinical value of serum urate may lie more in risk stratification and integrated management than in serving as a single therapeutic target for all renal outcomes.

Hepatic and metabolic liver disease has emerged as another important component of the gout comorbidity network. UK Biobank-based prospective and causal-inference studies have examined the relationship between gout and metabolic dysfunction-associated steatotic liver disease from both directions. One study suggested that gout may contribute to metabolic dysfunction-associated steatotic liver disease (MASLD) through gut microbiota and inflammatory mediators, whereas another found that MASLD was associated with a higher subsequent risk of gout^[31,89]. These findings support a bidirectional metabolic-inflammatory framework rather than a simple one-way causal pathway. Clinically, patients with gout, especially those with obesity, diabetes, or dyslipidemia, may benefit from evaluation of liver metabolic health as part of comprehensive risk management.

UK Biobank studies have also extended gout research beyond traditional metabolic and cardiovascular outcomes. An integrated cohort, Mendelian randomization, and mediation analysis suggested that impaired pulmonary function was associated with a higher risk of gout, with possible mediation through serum urate and inflammatory biomarkers^[30]. Another UK Biobank analysis examined the joint association of serum urate and healthy diet with chronic obstructive pulmonary disease incidence^[90]. These studies suggest that respiratory health may be connected to urate metabolism and systemic inflammation, although the clinical directionality remains under investigation.

During the COVID-19 pandemic, UK Biobank analyses reported that gout was associated with increased risks of COVID-19 diagnosis or COVID-19-related death, with some evidence of stronger relative associations among women^[29,91]. These findings should be interpreted cautiously because the association may reflect comorbid obesity, kidney disease, cardiovascular disease, health-care access, vaccination status, and treatment availability. Nevertheless, they reinforce the broader clinical point that patients with gout often carry a high burden of conditions that may increase vulnerability during systemic illness.

Mortality-related analyses further support the importance of considering serum urate within clinical context. In individuals with diabetes or chronic kidney disease, serum urate and hyperuricemia have been associated with all-cause or cardiovascular mortality, with some studies suggesting nonlinear or J-shaped patterns^[92,93]. These findings imply that both very high and very low urate levels may have different prognostic meanings in high-risk populations. However, they should not be interpreted as evidence that artificially maintaining a specific urate level improves survival. Rather, serum urate may help identify patients with a higher burden of metabolic, renal, and cardiovascular risk.

Several UK Biobank and genetic studies have explored associations between serum urate, gout, and less traditional clinical outcomes, including neurodegenerative disorders, cancer, bone mineral density, and erectile dysfunction^[94-100]. These studies broaden the clinical scope of urate and gout research, but the evidence is heterogeneous and often endpoint-specific. For example, serum urate may show different associations across neurodegenerative outcomes, cancer sites, or bone-related phenotypes. Mendelian randomization results are also not uniformly supportive of direct causal effects. At present, these findings are best viewed as hypothesis-generating rather than as indications for routine disease-specific screening in all patients with gout.

Overall, UK Biobank-based research supports a clinically useful view of gout as part of a systemic comorbidity network. The most actionable evidence relates to cardiometabolic disease, kidney function, metabolic liver disease, and high-risk infectious or mortality contexts. For clinicians, the practical implication is not to treat every reported association as causal, but to use gout as a prompt for integrated assessment of cardiovascular risk, renal function, metabolic health, liver disease risk, medication exposures, and lifestyle factors. This approach may enhance the clinical value of gout care beyond urate lowering while avoiding overinterpretation of observational associations.